ArticleBMC microbiology2025
Incidence and antimicrobial resistance of non-typhoidal Salmonella enterica in stool samples from children under five in peri-urban Ouagadougou, Burkina Faso.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antibiotic Resistance Trends and Prescribing Patterns in Pediatric Non-TyphoidalInfection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundNon-typhoidal Salmonella (NTS) causes significant illness worldwide, particularly in sub-Saharan Africa. Poor sanitation, limited healthcare, and rising antimicrobial resistance (AMR) worsen its impact on children under five. This study estimated the incidence and described AMR patterns of NTS among children under five in peri-urban Ouagadougou, Burkina Faso.
methodsA 12-month longitudinal cohort (ShigaPlexIM baseline study) was conducted in peri-urban Ouagadougou, Burkina Faso. Between December 2020 and March 2021, 750 children under five were enrolled and followed individually for 12 months, with study activities spanning 16 months in total. Stool samples were collected during diarrheal episodes and scheduled visits. Salmonella spp. was identified by stool culture, and antimicrobial susceptibility testing (AST) was performed using the Kirby-Bauer disc diffusion method per CLSI 2020 guidelines. Incidence rates were calculated using survival analysis over child-months of follow-up.
resultsOf 750 children enrolled, 680 (90.7%) completed follow-up, contributing 7,992.9 child-months. Salmonella was isolated from 97 of 2,401 (4.0%) stool samples. After excluding 33 isolates (29 prevalent cases and 4 typhoidal cases), 64 incident NTS cases were identified, resulting in an incidence rate of 8.0 per 1,000 child-months (95% CI: 6.3-10.2). The highest incidence was observed among children aged 12-23 months (10.3, 95% CI: 6.7-15.6) and in males (8.7, 95% CI: 6.3-12.1); however, sex differences were not significant (IRR = 0.75, 95% CI: 0.49-1.15, p = 0.184). Incidence in diarrheal stools was 43.7 per 1,000 child-months (95% CI: 23.5-81.2). All isolates were fully susceptible to imipenem, ciprofloxacin, ceftriaxone, and aztreonam. High susceptibility (≥ 96.7%) was observed for ceftazidime, cefotaxime, chloramphenicol, cefepime, and tobramycin. Moderate resistance was found for trimethoprim-sulfamethoxazole (4.4%), ampicillin (5.6%), nalidixic acid (5.6%), and streptomycin (6.7%). Resistance to tetracycline was highest at 74.4%. Multidrug resistance (MDR) was detected in 4.4% of isolates.
conclusionThis study demonstrates a substantial burden of NTS infections in children under five in peri-urban Burkina Faso. Although MDR prevalence was low, high tetracycline resistance indicates widespread circulation of resistant strains. Continuous AMR surveillance is essential to guide treatment and preserve antibiotic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.